Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Nanopeptide (Qingdao) Biotechnology Ltd. maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to 1 distinct examiner working within 1 distinct art unit. This structure indicates a high degree of consistency in the examination process, as the same technical standards from 1 distinct art unit will likely apply to the entire active portfolio.
The busiest examiner for the company is POLIAKOVA-GEORGAN, EKATERINA, who is responsible for 2 busiest examiner pending actions. Because 1 distinct examiner is handling all 2 pending office actions, the company's success in the Biotechnology & Pharmaceuticals sector is currently dependent on the perspectives of a single individual. This centralization allows for a unified response strategy across the 2 pending office actions, as the practitioner only needs to account for the specific requirements of POLIAKOVA-GEORGAN, EKATERINA.
Having 2 pending office actions concentrated in 1 distinct art unit reduces the risk of conflicting requirements that can arise when multiple units are involved. The workload of 2 busiest examiner pending actions suggests a focused engagement with the patent office. Practitioners should leverage this concentration to build a consistent rapport with the 1 distinct examiner assigned to these Biotechnology & Pharmaceuticals matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 2 | 64.0% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130418 | Target Ligand | POLIAKOVA-GEORGAN, EKATERINA | 30d overdue |
| 18092202 | SIRNA OF ANGPTL3 AND USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18130418 | Target Ligand | POLIAKOVA-GEORGAN, EKATERINA | 1637 | DP | Final Rejection | 30d overdue | Pending | Apr 03, 2023 |
| 18092202 | SIRNA OF ANGPTL3 AND USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102DP | Final Rejection | 30d overdue | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial